Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jun;12(3):138-144.
doi: 10.14740/jh1124. Epub 2023 Jun 30.

Donor Cell Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation

Ahmed Khattab  1   2 , Sunita Patruni  3 , Gina Patrus  4 , Yazan Samhouri  4 , Salman Fazal  4 , John Lister  4
Affiliations
Case Reports

Donor Cell Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation

Ahmed Khattab et al. J Hematol. 2023 Jun.

Abstract

Approximately 25,000 allogeneic transplants are performed annually worldwide; a figure that has steadily increased over the past three decades. The study of transplant recipient survivorship has become a cogent topic and post-transplant donor cell pathology warrants further study. Donor cell leukemia (DCL) is a rare but serious complication of allogeneic stem cell transplantation (SCT) where the recipient develops a form leukemia originating from the donor cells used for transplantation. Detection of abnormalities predicting donor cell pathology might inform donor selection, and the design of survivorship programs for early detection of these abnormalities might allow therapeutic intervention earlier in the disease course. We present four recipients of allogeneic hematopoietic stem cell transplant (HSCT) from our institution who developed donor cell abnormalities allogeneic SCT, highlighting their clinical characteristics and challenges.

Keywords: Age-related clonal hematopoiesis; Allogeneic; Clonal hematopoiesis of indeterminant potential; Hematopoietic stem cell transplantation; Stem cell transplant.

PubMed Disclaimer

Conflict of interest statement

The other authors have no conflict of interest to make. Institutional IRB approval was granted for the conduct of this study.

Similar articles

See all similar articles

References

    1. Goyal SD, Slade M, Shanley R, Szer J, Grigg AP, Kennedy GA. Donor cell leukemia: a review. Bone Marrow Transplantation. 2019;54(8):1135–1141.
    1. Smith M, Arthur C, Robinson S. Donor cell leukemia - a review. Bone Marrow Transplantation. 2010;45(3):351–357.
    1. Wang ML, Sandmaier BM, Maloney DG. Donor cell leukemia after allogeneic stem cell transplantation: risk factors, treatment, and prevention. Biology of Blood and Marrow Transplantation. 2020;26(7):e163–e169.
    1. Majhail NS. Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2017;10(4):220–227. doi: 10.1016/j.hemonc.2017.05.009. - DOI - PMC - PubMed
    1. Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, Cahn JY. et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341(1):14–21. doi: 10.1056/NEJM199907013410103. - DOI - PubMed

Publication types

LinkOut - more resources